The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: Clinical relevance

Experimental Neurology

Volumn 221, Issue 2, 2010, Pages 329-334

  Sonsalla, Patricia K ^a   Wong, Lai Yoong ^a   Winnik, Bozena ^b   Buckley, Brian ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Epilepsy; MAO B; Mice; MPTP; Parkinson's disease; Zonisamide

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTICONVULSIVE AGENT; SELEGILINE; TYROSINE 3 MONOOXYGENASE; ZONISAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG DOSE COMPARISON; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; IC 50; IN VITRO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; ISOXAZOLES; MALE; MASS SPECTROMETRY; MICE; MONOAMINE OXIDASE; MPTP POISONING; REGRESSION (PSYCHOLOGY); TYROSINE 3-MONOOXYGENASE;

EID: 73949127414     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.11.018     Document Type: Article

References (34)

1. Alfinito P.D., Wang S.P., Manzino L., Rijhsinghani S., Zeevalk G.D., and Sonsalla P.K. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J. Neurosci. 23 (2003) 10982-10987
2. Asanuma M., and Miyazaki I. Protective effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone-related neurotoxicity. Society for Neuroscience Program Nol 158 (2007) 1
3. Asanuma M., Miyazaki I., Diaz-Corrales F.J., Miyoshi K., Ogawa N., and Murata M. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci. Res. 60 (2008) 106-113
4. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin. Neuropharmacol. 30 (2007) 230-240
5. Borowicz K.K., Jaszczyk B., Luszczki J.J., and Czuczwar S.J. Interactions between two enantiomers of losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model-an isobolographic analysis. Eur. J. Pharmacol. 567 (2007) 110-116
6. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli Jr. N., and Schwarzschild M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21 (2001) RC143
7. Czapinski P., Blaszczyk B., and Czuczwar S.J. Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem. 5 (2005) 3-14
8. Giovanni A., Sieber B.A., Heikkila R.E., and Sonsalla P.K. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257 (1991) 691-697
9. Heikkila R.E., Kindt M.V., Sonsalla P.K., Giovanni A., Youngster S.K., McKeown K.A., and Singer T.P. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 6172-6176
10. Khalil A.A., Davies B., and Castagnoli Jr. N. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorganic Med. Chem. 14 (2006) 3392-3398
11. Kito M., Maehara M., and Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5 (1996) 115-119
12. Kong L.D., Cheng C.H., Tan R.X., and Cheng C.H.K. Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones. J. Ethnopharmacol. 91 (2004) 351-355
13. Meldrum B.S., and Rogawski M.A. Molecular targets for antiepileptic drug development. Neurotherapeutics 4 (2007) 18-61
14. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther. Drug Monit. 20 (1998) 593-597
15. Minato H., Kikuta C., Fujitani B., and Masuda Y. Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia 38 (1997) 975-980
16. Moy L.Y., Zeevalk G.D., and Sonsalla P.K. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. J. Neurochem. 74 (2000) 1656-1665
17. Murakami T., Okada M., Kawata Y., Zhu G., Kamata A., and Kaneko S. Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br. J. Pharmacol. 134 (2001) 507-520
18. Murata M., Hasegawa K., Kanazawa I., Murata M., Hasegawa K., Kanazawa I., The Japan Zonisamide on, and P. D. S. G. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. [see comment][erratum appears in Neurology. 2007 Jul 3;69(1):120]. Neurology 68 (2007) 45-50
19. Nagatomo I., Akasaki Y., Nagase F., Nomaguchi M., and Takigawa M. Relationships between convulsive seizures and serum and brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse. Brain Res. 731 (1996) 190-198
20. Nagatomo I., Akasaki Y., Uchida M., Tominaga M., Hashiguchi W., and Takigawa M. Effects of combined administration of zonisamide and valproic acid or phenytoin to nitric oxide production, monoamines and zonisamide concentrations in the brain of seizure-susceptible EL mice. Brain Res. Bull. 53 (2000) 211-218
21. Okada M., Kaneko S., Hirano T., Mizuno K., Kondo T., Otani K., and Fukushima Y. Effects of zonisamide on dopaminergic system. Epilepsy Res. 22 (1995) 193-205
22. Peters D.H., and Sorkin E.M. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 45 (1993) 760-787
23. Prasad K., Winnik B., Thiruchelvam M.J., Buckley B., Mirochnitchenko O., and Richfield E.K. Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain. Environ. Health Perspect. 115 (2007) 1448-1453
24. Quinn L.P., Crook B., Hows M.E., Vidgeon-Hart M., Chapman H., Upton N., Medhurst A.D., and Virley D.J. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br. J. Pharmacol. 154 (2008) 226-233
25. Rocha M.A., Crockett D.P., Wong L.Y., Richardson J.R., and Sonsalla P.K. Na(+)/H(+) exchanger inhibition modifies dopamine neurotransmission during normal and metabolic stress conditions. J. Neurochem. 106 (2008) 231-243
26. Shih J.C., Chen K., and Ridd M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 22 (1999) 197-217
27. Sobieszek G., Borowicz K.K., Kimber-Trojnar Z., Malek R., Piskorska B., and Czuczwar S.J. Zonisamide: a new antiepileptic drug. Pol. J. Pharmacol. 55 (2003) 683-689
28. Sonsalla P.K., Youngster S.K., Kindt M.V., and Heikkila R.E. Characteristics of 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J. Pharmacol. Exp. Ther. 242 (1987) 850-857
29. Tokumaru J., Ueda Y., Yokoyama H., Nakajima A., Doi T., Mitsuyama Y., Ohya-Nishiguchi H., and Kamada H. In vivo evaluation of hippocampal anti-oxidant ability of zonisamide in rats. Neurochem. Res. 25 (2000) 1107-1111
30. Ueda Y., Doi T., Tokumaru J., Nakajima A., and Nagatomo K. In vivo evaluation of the effect of zonisamide on the hippocampal redox state during kainic acid-induced seizure status in rats. Neurochem. Res. 30 (2005) 1117-1121
31. Yabe H., Choudhury M.E., Kubo M., Nishikawa N., Nagai M., and Nomoto M. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J. Pharmacol. Sci. 110 (2009) 64-68
32. Yang M., Soohoo D., Soelaiman S., Kalla R., Zablocki J., Chu N., Leung K., Yao L., Diamond I., Belardinelli L., and Shryock J.C. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 375 (2007) 133-144
33. Youngster S.K., Sonsalla P.K., and Heikkila R.E. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 48 (1987) 929-934
34. Zhou C.X., Kong L.D., Ye W.C., Cheng C.H., and Tan R.X. Inhibition of xanthine and monoamine oxidases by stilbenoids from Veratrum taliense. Planta Med. 67 (2001) 158-161